Ignite Creation Date:
2024-05-06 @ 3:18 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04589390
Status:
UNKNOWN
Last Update Posted:
2020-10-19
First Post:
2020-10-08
Brief Title:
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Sponsor:
University of Sao Paulo General Hospital
Organization:
University of Sao Paulo General Hospital
Study Overview
Official Title:
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Status:
UNKNOWN
Status Verified Date:
2020-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SELSCH
Brief Summary:
Pulmonary arterial hypertension PAH is a severe progressive and potentially fatal disease that impairs the pulmonary circulation and leads to right ventricular failure One of the world most prevalent etiologies of PAH is schistosomiasis-associated pulmonary arterial hypertension Sch-PAH New drugs have emerged to treat other forms of PAH but their benefits cannot be automatically translated for Sch-PAH patients since this etiology was not included in the pivotal PAH trials One of the most promising therapies for the treatment of PAH to emerge in recent years is selexipag an oral IP receptor agonist which acts on the prostacyclin pathway The present study aims to evaluate the efficacy safety and tolerability of selexipague for the treatment of schistosomiasis-associated pulmonary arterial hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None